Ashton Thomas Private Wealth LLC Has $349,000 Holdings in CVS Health Co. (NYSE:CVS)

Ashton Thomas Private Wealth LLC lessened its stake in CVS Health Co. (NYSE:CVS - Free Report) by 52.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,766 shares of the pharmacy operator's stock after selling 8,483 shares during the quarter. Ashton Thomas Private Wealth LLC's holdings in CVS Health were worth $349,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Callan Family Office LLC acquired a new stake in shares of CVS Health in the 4th quarter valued at approximately $905,000. EagleClaw Capital Managment LLC lifted its holdings in CVS Health by 3.4% during the 4th quarter. EagleClaw Capital Managment LLC now owns 6,135 shares of the pharmacy operator's stock valued at $275,000 after purchasing an additional 200 shares during the last quarter. E Fund Management Co. Ltd. lifted its holdings in CVS Health by 87.9% during the 4th quarter. E Fund Management Co. Ltd. now owns 9,390 shares of the pharmacy operator's stock valued at $422,000 after purchasing an additional 4,392 shares during the last quarter. Candriam S.C.A. lifted its holdings in CVS Health by 13.4% during the 4th quarter. Candriam S.C.A. now owns 110,200 shares of the pharmacy operator's stock valued at $4,947,000 after purchasing an additional 13,040 shares during the last quarter. Finally, Lindbrook Capital LLC lifted its holdings in CVS Health by 3.8% during the 4th quarter. Lindbrook Capital LLC now owns 6,772 shares of the pharmacy operator's stock valued at $304,000 after purchasing an additional 248 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company's stock.

CVS Health Stock Performance

CVS Health stock opened at $64.98 on Wednesday. CVS Health Co. has a 12-month low of $43.56 and a 12-month high of $80.75. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. The business's 50-day moving average price is $57.24 and its two-hundred day moving average price is $56.83. The stock has a market cap of $81.92 billion, a PE ratio of 17.75, a P/E/G ratio of 0.98 and a beta of 0.53.

Remove Ads

CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. As a group, analysts expect that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Thursday, January 23rd were paid a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.09%. The ex-dividend date was Thursday, January 23rd. CVS Health's payout ratio is 72.68%.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on CVS shares. Truist Financial raised their price target on CVS Health from $60.00 to $76.00 and gave the company a "buy" rating in a report on Thursday, February 13th. JPMorgan Chase & Co. increased their price objective on CVS Health from $80.00 to $81.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 18th. Deutsche Bank Aktiengesellschaft upgraded CVS Health from a "hold" rating to a "buy" rating and set a $66.00 price objective on the stock in a research report on Tuesday, December 3rd. Piper Sandler lowered their price objective on CVS Health from $72.00 to $64.00 and set an "overweight" rating on the stock in a research report on Monday, November 25th. Finally, StockNews.com upgraded CVS Health from a "sell" rating to a "hold" rating in a research report on Thursday, February 13th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, CVS Health presently has an average rating of "Moderate Buy" and an average target price of $69.83.

Insider Activity

In other news, Director Michael F. Mahoney purchased 30,000 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were purchased at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the purchase, the director now owns 39,356 shares of the company's stock, valued at $2,625,045.20. This trade represents a 320.65 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the transaction, the senior vice president now directly owns 8,394 shares in the company, valued at approximately $556,941.90. This represents a 47.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.24% of the company's stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.